International Research Highlight
Patients with unresectable hepatocellular carcinoma (HCC) typically receive frontline monotherapy with the multikinase inhibitors sorafenib or lenvatinib. These agents provide limited survival benefits and are associated with considerable toxicities and poor quality-of-life (QOL) outcomes. Immune-checkpoint inhibitors (ICIs) have also been tested as monotherapies in patients with HCC, with disappointing outcomes to date. Now the results of the phase III IMbrave150 trial show that the combination of an ICI with an anti-VEGFA antibody leads to promising activity in this setting.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten